Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Aspirin in primary prevention--good news and bad news.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • NAICS/Industry Codes:
      325411 Medicinal and Botanical Manufacturing
      325410 Pharmaceutical and medicine manufacturing
      541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
    • Abstract:
      The article presents a meta-analysis of nine randomized trials to clarify the balance and benefits of aspirin in the primary prevention of cardiovascular disease. It states that for secondary prevention, the benefits of aspirin therapy substantially exceed the risks of major gastrointestinal or other major extracranial bleeds. However, the meta-analysis showed that for primary prevention, routine use of aspirin is not warranted and treatment decisions should be done on a case-to-case basis.
    • Author Affiliations:
      1Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, Research Park, Building 3848, Suite 310, Boca Raton, FL 33431, USA
      2Clinical Trial and Epidemiology Service Unit, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK
    • ISSN:
      1759-5002
    • Accession Number:
      10.1038/nrcardio.2012.26
    • Accession Number:
      76924589
  • Citations
    • ABNT:
      HENNEKENS, C. H.; BAIGENT, C. Aspirin in primary prevention--good news and bad news. Nature Reviews Cardiology, [s. l.], v. 9, n. 5, p. 262–263, 2012. DOI 10.1038/nrcardio.2012.26. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=76924589&custid=s8280428. Acesso em: 25 fev. 2020.
    • AMA:
      Hennekens CH, Baigent C. Aspirin in primary prevention--good news and bad news. Nature Reviews Cardiology. 2012;9(5):262-263. doi:10.1038/nrcardio.2012.26.
    • APA:
      Hennekens, C. H., & Baigent, C. (2012). Aspirin in primary prevention--good news and bad news. Nature Reviews Cardiology, 9(5), 262–263. https://doi.org/10.1038/nrcardio.2012.26
    • Chicago/Turabian: Author-Date:
      Hennekens, Charles H., and Colin Baigent. 2012. “Aspirin in Primary Prevention--Good News and Bad News.” Nature Reviews Cardiology 9 (5): 262–63. doi:10.1038/nrcardio.2012.26.
    • Harvard:
      Hennekens, C. H. and Baigent, C. (2012) ‘Aspirin in primary prevention--good news and bad news’, Nature Reviews Cardiology, 9(5), pp. 262–263. doi: 10.1038/nrcardio.2012.26.
    • Harvard: Australian:
      Hennekens, CH & Baigent, C 2012, ‘Aspirin in primary prevention--good news and bad news’, Nature Reviews Cardiology, vol. 9, no. 5, pp. 262–263, viewed 25 February 2020, .
    • MLA:
      Hennekens, Charles H., and Colin Baigent. “Aspirin in Primary Prevention--Good News and Bad News.” Nature Reviews Cardiology, vol. 9, no. 5, May 2012, pp. 262–263. EBSCOhost, doi:10.1038/nrcardio.2012.26.
    • Chicago/Turabian: Humanities:
      Hennekens, Charles H., and Colin Baigent. “Aspirin in Primary Prevention--Good News and Bad News.” Nature Reviews Cardiology 9, no. 5 (May 2012): 262–63. doi:10.1038/nrcardio.2012.26.
    • Vancouver/ICMJE:
      Hennekens CH, Baigent C. Aspirin in primary prevention--good news and bad news. Nature Reviews Cardiology [Internet]. 2012 May [cited 2020 Feb 25];9(5):262–3. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=76924589&custid=s8280428